Skip to content

Journal of Nuclear Medicine

ISSN 2159-662X, 1535-5667

6 papers in the library · 100 citations · publishing 2010-2022

Papers

Sort Most recent Most cited

Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine

Journal of Nuclear Medicine September 29, 2022 Tudor M. Ionescu, Mario Amend, Tadashi Watabe et al. 19 citations

Psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA) have attracted increasing interest in recent years because of their therapeutic potential in psychiatric disorders. To understand the acute effects of psychedelic drugs in vivo, blood-oxygenation-level-dependent (BOLD) functional MRI (fMRI) has been widely used. In particular, fMRI studies have suggested that MDMA leads to...

DOI: 10.2967/jnumed.122.264391 (opens in new tab) Full text (opens in new tab) MDMA Serotonin transporter Hemodynamics Hallucinogen +4

A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients

Journal of Nuclear Medicine July 17, 2020 O. Kulterer, S. Pfaff, Wolfgang Wadsak et al.

99mTc-PHC-102 is a 99mTc-labeled derivative of acetazolamide, a high-affinity small organic ligand of carbonic anhydrase IX (CAIX). 99mTc-PHC-102 has previously shown favorable in vivo biodistribution properties in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer. In this study, we aimed to explore the targeting performance of 99mTc-PHC-102 in SPECT in...

The Use of Microdosing in the Development of Small Organic and Protein Therapeutics

Journal of Nuclear Medicine May 25, 2017 Mats Bergström 31 citations

Microdosing as a regulatory concept was introduced to facilitate exploratory studies in humans. The concept involves the use of very low doses of a radionuclide-labeled compound for imaging studies or for assessing plasma pharmacokinetics using equipment that has a highly sensitive readout. The supporting principle is that use of these low doses for a limited time in well-controlled, small...

DOI: 10.2967/jnumed.116.188037 (opens in new tab) Pharmacology Drug development Pharmacokinetics Small molecule

Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.

Journal of Nuclear Medicine November 2015 Tal Burt, Douglas C Rouse, Kihak Lee et al.

Intraarterial microdosing (IAM) is a novel drug development approach combining intraarterial drug delivery and microdosing. We aimed to demonstrate that IAM leads to target exposure similar to that of systemic full-dose administration but with minimal systemic exposure. IAM could enable the safe, inexpensive, and early study of novel drugs at the first-in-human stage and the study of...

In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.

Journal of Nuclear Medicine June 2011 Arturo A Vitale, Alicia B Pomilio, Carlos O Cañellas et al.

N,N-dimethyltryptamine (DMT), a strong psychodysleptic drug, has been found in higher plants, shamanic hallucinogenic beverages, and the urine of schizophrenic patients. The aim of this work was to gain better knowledge on the relationship between this drug and hallucinogenic processes by studying DMT behavior in comparison with tryptamine. (131)I-labeled DMT and tryptamine were injected into...

Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET

Journal of Nuclear Medicine October 18, 2010 Anders Ettrup, Mikael Palner, Nic Gillings et al. 50 citations

UNLABELLED: PET brain imaging of the serotonin 2A (5-hydroxytryptamine 2A, or 5-HT(2A)) receptor has been widely used in clinical studies, and currently, several well-validated radiolabeled antagonist tracers are used for in vivo imaging of the cerebral 5-HT(2A) receptor. Access to 5-HT(2A) receptor agonist PET tracers would, however, enable imaging of the active, high-affinity state of...